An Investigator-initiated, Single-center Academic Study in Healthy Transgender and Cisgender Persons Aged Between 18 and 40 Years to Investigate Gender and Sex Differences in Immune Responses to Meningococcal Serogroup B Vaccination
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Acronyms Vaxxygender
Most Recent Events
- 25 Feb 2025 New trial record